Activins, follistatins and inhibins in postmenopausal osteoporosis: A proof of concept, case-control study.

[1]  J. George,et al.  Local versus systemic control of bone and skeletal muscle mass by components of the transforming growth factor-β signaling pathway , 2021, Proceedings of the National Academy of Sciences.

[2]  C. Mantzoros,et al.  Circulating profile of Activin-Follistatin-Inhibin Axis in women with hypothalamic amenorrhea in response to leptin treatment. , 2020, Metabolism: clinical and experimental.

[3]  Yun‐Sil Lee,et al.  GDF11 promotes osteogenesis as opposed to MSTN, and follistatin, a MSTN/GDF11 inhibitor, increases muscle mass but weakens bone , 2020, Proceedings of the National Academy of Sciences.

[4]  J. V. van Leeuwen,et al.  Follistatin Effects in Migration, Vascularization, and Osteogenesis in vitro and Bone Repair in vivo , 2019, Front. Bioeng. Biotechnol..

[5]  M. Eijken,et al.  A follistatin‐based molecule increases muscle and bone mass without affecting the red blood cell count in mice , 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  C. Mantzoros,et al.  Regulation of the activins-follistatins-inhibins axis by energy status: Impact on reproductive function. , 2018, Metabolism: clinical and experimental.

[7]  M. Eijken,et al.  A soluble activin type IIA receptor mitigates the loss of femoral neck bone strength and cancellous bone mass in a mouse model of disuse osteopenia. , 2018, Bone.

[8]  C. Mantzoros,et al.  Circulating follistatin displays a day-night rhythm and is associated with muscle mass and circulating leptin levels in healthy, young humans. , 2016, Metabolism: clinical and experimental.

[9]  C. Mantzoros,et al.  Ciliary neurotrophic factor upregulates follistatin and Pak1, causes overexpression of muscle differentiation related genes and downregulation of established atrophy mediators in skeletal muscle. , 2016, Metabolism: clinical and experimental.

[10]  S. Polyzos,et al.  Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment , 2013, Osteoporosis International.

[11]  M. Hamrick,et al.  Effects of the activin A–myostatin–follistatin system on aging bone and muscle progenitor cells , 2013, Experimental Gerontology.

[12]  R. Baron,et al.  Activin receptor signaling: a potential therapeutic target for osteoporosis. , 2012, Current molecular pharmacology.

[13]  C. Mantzoros,et al.  Short-term energy deprivation alters activin a and follistatin but not inhibin B levels of lean healthy women in a leptin-independent manner. , 2011, The Journal of clinical endocrinology and metabolism.

[14]  Mary T. Brinkoetter,et al.  Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women. , 2011, Metabolism: Clinical and Experimental.

[15]  C. Mantzoros,et al.  Energy deprivation alters in a leptin- and cortisol-independent manner circulating levels of activin A and follistatin but not myostatin in healthy males. , 2011, The Journal of clinical endocrinology and metabolism.

[16]  Mary T. Brinkoetter,et al.  Leptin treatment reduces body fat but does not affect lean body mass or the myostatin-follistatin-activin axis in lean hypoleptinemic women. , 2011, American journal of physiology. Endocrinology and metabolism.

[17]  M. Bouxsein,et al.  Inhibiting activin‐A signaling stimulates bone formation and prevents cancer‐induced bone destruction in vivo , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  R. Baron,et al.  A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. , 2010, Bone.

[19]  K. Tsuchida,et al.  Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin. , 2009, American journal of physiology. Endocrinology and metabolism.

[20]  Yijun Yang,et al.  Single‐Dose, Randomized, Double‐Blind, Placebo‐Controlled Study of ACE‐011 (ActRIIA‐IgG1) in Postmenopausal Women , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  D. Gaddy.  Inhibin and the regulation of bone mass , 2008, Current osteoporosis reports.

[22]  S. Khosla,et al.  Bone turnover across the menopause transition: correlations with inhibins and follicle-stimulating hormone. , 2006, The Journal of clinical endocrinology and metabolism.

[23]  S. Badur,et al.  Ovarian aging and bone metabolism in menstruating women aged 35-50 years. , 2005, Maturitas.

[24]  S. Choe,et al.  Activins and Inhibins and Their Signaling , 2004, Annals of the New York Academy of Sciences.

[25]  C. Mantzoros,et al.  The role of leptin in regulating neuroendocrine function in humans. , 2004, The Journal of nutrition.

[26]  C. Mantzoros,et al.  Leptin in relation to resumption of menses in women with anorexia nervosa , 1998, Molecular Psychiatry.

[27]  M. Bouxsein,et al.  Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis). , 2010, Bone.

[28]  R. Jilka,et al.  Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures. , 2002, Endocrinology.